We could not find any results for:
Make sure your spelling is correct or try broadening your search.
- QLT Ophthalmics, Inc. will market Visudyne(R) to retinal specialists across the U.S.- VANCOUVER, Dec. 22 /PRNewswire-FirstCall/ -- QLT Inc. (NASDAQ: QLTI; TSX: QLT) ("QLT" or the "Company") is...
VANCOUVER, Dec. 15 /PRNewswire-FirstCall/ -- QLT Inc. (NASDAQ: QLTI; TSX: QLT) ("QLT" or the "Company") today announced that it has initiated enrollment in a Phase Ib trial of QLT091001 in...
VANCOUVER, Dec. 9 /PRNewswire-FirstCall/ -- QLT Inc. (NASDAQ: QLTI; TSX: QLT) ("QLT" or the "Company") welcomed the 6-month results from the Novartis-sponsored EVEREST study which were presented...
VANCOUVER, Nov. 25 /PRNewswire-FirstCall/ -- QLT Inc. (NASDAQ: QLTI; TSX: QLT) ("QLT" or the "Company") today announced the settlement of its litigation with the General Hospital Corporation...
VANCOUVER, Oct. 28 /PRNewswire-FirstCall/ -- QLT Inc. (NASDAQ: QLTI; TSX: QLT) ("QLT") announced that the Toronto Stock Exchange ("TSX") has accepted the notice of QLT's intention to make a...
VANCOUVER, Oct. 27 /PRNewswire-FirstCall/ -- QLT Inc. (NASDAQ: QLTI; TSX: QLT) ("QLT" or the "Company") today announced that its board of directors has authorized the repurchase of up to 5% of...
QLT SEPARATELY ANNOUNCES SHARE REPURCHASE PROGRAM VANCOUVER, Oct. 27 /PRNewswire-FirstCall/ -- QLT Inc. (NASDAQ: QLTI; TSX: QLT) ("QLT" or the "Company") today reported financial results for the...
QLT Inc. (QLTI) will soon have exclusive U.S. sales and marketing rights to Visudyne after reaching a restructured agreement with Novartis Pharma AG (NVG), its marketing partner. Visudyne was the...
RECEIVES EXCLUSIVE U.S. RIGHTS AND WILL RECEIVE A ROYALTY ON SALES OUTSIDE THE U.S. VANCOUVER, Oct. 19 /PRNewswire-FirstCall/ -- QLT Inc. (NASDAQ: QLTI; TSX: QLT) ("QLT" or the "Company") today...
VANCOUVER, Oct. 1 /PRNewswire-FirstCall/ -- QLT Inc. (NASDAQ: QLTI; TSX: QLT) ("QLT" or the "Company") today announced that it has completed the sale of all of the shares of its wholly-owned...
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | -0.4571 | -1.97025862069 | 23.2 | 23.5 | 22.5 | 4423 | 22.91885401 | SP |
4 | -1.5571 | -6.40781893004 | 24.3 | 24.33 | 22.49 | 4190 | 23.47072619 | SP |
12 | -2.1071 | -8.47927565392 | 24.85 | 25.1 | 22.49 | 8184 | 23.77691576 | SP |
26 | -2.1071 | -8.47927565392 | 24.85 | 25.1 | 22.49 | 8184 | 23.77691576 | SP |
52 | -2.1071 | -8.47927565392 | 24.85 | 25.1 | 22.49 | 8184 | 23.77691576 | SP |
156 | -2.1071 | -8.47927565392 | 24.85 | 25.1 | 22.49 | 8184 | 23.77691576 | SP |
260 | -2.1071 | -8.47927565392 | 24.85 | 25.1 | 22.49 | 8184 | 23.77691576 | SP |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions